Safety and Efficacy of PHP in the Treatment of Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)
Status:
Completed
Trial end date:
2004-05-01
Target enrollment:
Participant gender:
Summary
To determine the safety and effectiveness of pyridoxylated hemoglobin polyoxyethylene
conjugate (PHP) administered by continuous intravenous (IV) infusion in systemic inflammatory
response syndrome (SIRS) patients with shock. PHP is a human-derived chemically modified
hemoglobin preparation. PHP selectively scavenges excess nitric oxide (NO) and does so in a
catalytic, concentration-dependent reaction that results in the formation of the non-toxic NO
metabolite, nitrate. PHP is postulated to reduce excess, toxic levels of NO while allowing
critical beneficial levels of the molecule to persist.